Nuvalent
patient population heavily solid tumors phase characteristic age median range female tumor type pancreatic adenocarcinoma non smoker history of metastases measurable lesions all treated data as of for patients treated by all data shown as unless otherwise specified central nervous system eastern oncology group performance status non smell lung cancer response evaluation criteria in version tyrosine kinase includes patients with untreated lesions categories are not mutually exclusive source a treatment prior lines of anticancer treatment median range prior treatments without chemotherapy and chemotherapy without chemotherapy and received chemotherapy and other all treated an i | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
April 2024
Slide
32 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
patient population heavily alk solid tumors phase characteristic age median range female non smoker tumor type pancreatic adenocarcinoma atypical carcinoid lung history of metastases fusion secondary mutation single mutation compound i mutations single or compound all treated data cut me all data shown as unless otherwise generation eastern coop response in performance non small version ase inhibit patients lesions not confirmed in all cases categories are not mutually exclusive source lin treatment history prior lines of anticancer treatment median range prior treatments chemotherapy received any or including and including and all treated | Nuvalent
Investor Presentation
February 2024
patient population heavily solid tumors phase characteristic age median range female tumor type pancreatic adenocarcinoma non smoker history of metastases measurable lesions punted data as of for patients treated by all data shown as unless otherwise specified central nervous system eastern oncology group performance status non lung cancer response evaluation criteria in version tyrosine kinase includes patients with untreated lesions categories are not mutually exclusive source a treatment prior lines of anticancer treatment median range prior treatments without chemotherapy and chemotherapy without chemotherapy and chemotherapy received other cee | Nuvalent
Investor Presentation
February 2024
patient population heavily alk solid tumors phase characteristic age median range female non smoker tumor type pancreatic adenocarcinoma atypical carcinoid lung history of metastases fusion secondary mutation single mutation compound i mutations single or compound data cut off unless otherwise specified east generation performance status non small cell all treated response version tyrosine kinase inhibitor pat lesions not confirmed in all cases categories are not ally source lin treatment history prior lines of anticancer treatment median range prior treatments chemotherapy received any or including and including and all treated i | Nuvalent
Investor Presentation
January 2024
patient population heavily solid tumors phase characteristic age median range female tumor type pancreatic adenocarcinoma non smoker history of metastases measurable lesions data as of for patients treated by all data shown as unless otherwise ire eon includes patients with untreated lesions categories are not mutually exclusive source a treatment history prior lines of anticancer treatment median range prior treatments without chemotherapy and chemotherapy without chemotherapy and chemotherapy received other a | Nuvalent
Related slides by other companies
BioNTech
Results
November 2020
phase a dose patient demographics | BioNTech
Dare Bioscience
Investor Presentation
February 2023
dare proof of concept dare | Dare Bioscience
Wix
Results
November 2016
business outlook we are again raising our full year outlook for all key metrics by a significant amount as our financial performance in greatly exceeded our own expectations as a reminder our forward looking statements are based on current expectations and assumptions looking ahead to next year the consistent execution of our mission to deliver the most comprehensive operating system for small businesses along with our effective marketing strategy and disciplined financial management positions us very well for another year of exceptional top line growth strong margin expansion and positive cash flow we will continue to develop and release new products that resonate with our users and grow our brand globally we will provide more details on our financial outlook for on our next earnings call in for we now expect the following collections in the range of to million representing annual growth of compared to growth in our revised outlook is an increase from our prior full year range of to million our collections guidance is approximately million higher or to million on a constant currency basis this is slightly higher than we projected in due to continued depreciation in the against the us dollar revenue in the range of to million an increase from our prior range of to million adjusted in a range of to million an increase from our prior outlook of to million updated financial outlook | Wix
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io